GO:0032802 low-density lipoprotein particle receptor catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032802 describes the breakdown of the low-density lipoprotein (LDL) receptor, the protein that clears LDL cholesterol from the blood.
• The LDL receptor (LDLR) is a cell-surface receptor that binds apolipoprotein B100 on LDL particles and delivers cholesterol into cells through receptor-mediated endocytosis.
• Catabolism of the LDL receptor is a regulated process that controls how many receptors remain on the cell surface and therefore how much LDL is cleared.
• The E3 ubiquitin ligase IDOL (MYLIP) is a key regulator that ubiquitinates the LDL receptor and targets it for degradation in response to cellular cholesterol levels.
• Defects in LDL receptor function cause familial hypercholesterolemia, and altered LDL receptor catabolism contributes to cardiovascular and neurodegenerative disease biology.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models allow researchers to dissect each step of LDL receptor catabolism.
Description
GO:0032802, low-density lipoprotein particle receptor catabolic process, is the biological process by which the low-density lipoprotein (LDL) receptor molecule is broken down inside cells. The LDL receptor (LDLR) is a cell-surface glycoprotein that binds LDL particles through apolipoprotein B100 and mediates the uptake of cholesterol into cells. Because the number of LDL receptors on the cell surface determines how much LDL cholesterol is removed from the bloodstream, the rate at which these receptors are catabolized directly influences plasma cholesterol levels. Researchers study this process to understand cholesterol homeostasis, familial hypercholesterolemia, and the broader biology of receptor trafficking and degradation. The catabolic process is not simply a disposal mechanism; it is a regulated pathway that responds to cellular cholesterol status and hormonal signals. The LDL receptor was one of the first receptors for which receptor-mediated endocytosis and regulated degradation were described, making GO:0032802 a foundational term in cell biology. Modern structural and cellular studies continue to refine our understanding of how the LDL receptor binds its ligand and how its catabolism is controlled.
low-density lipoprotein particle receptor catabolic process At A Glance
| GO ID | GO:0032802 |
|---|---|
| GO term | low-density lipoprotein particle receptor catabolic process |
| Ontology | biological_process |
| Synonym | LDL receptor degradation; LDL receptor catabolism; low-density lipoprotein receptor breakdown |
| Major function | Breakdown of the LDL receptor, controlling receptor availability and cholesterol uptake |
| Key regulator | IDOL (MYLIP), an E3 ubiquitin ligase that targets LDLR for degradation |
| Cellular location | Cell surface, endosomes, and lysosomes where receptor degradation occurs |
| Related disease | Familial hypercholesterolemia and atherosclerosis |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, and biochemical assays |
What Is GO:0032802?
In simple terms, GO:0032802 is the process that breaks down the LDL receptor protein inside a cell. More formally, it encompasses the chemical reactions and pathways that result in the breakdown of a low-density lipoprotein particle receptor molecule, a macromolecule that combines with a hormone, neurotransmitter, drug, or intracellular messenger to initiate a change in cell function. This process includes the recognition, internalization, and degradation of the receptor, and it is distinct from the catabolism of the LDL particle itself.
Why Is low-density lipoprotein particle receptor catabolic process Important in Cell Biology?
The catabolism of the LDL receptor is central to cholesterol homeostasis because it determines how many receptors are available to clear LDL from the blood. When LDL receptor catabolism is accelerated, fewer receptors remain on the cell surface, LDL clearance decreases, and plasma cholesterol rises, which is a major risk factor for atherosclerosis and cardiovascular disease. Conversely, understanding the signals that control LDL receptor degradation may reveal therapeutic strategies to stabilize the receptor and lower cholesterol. The process also serves as a paradigm for regulated receptor downregulation and ubiquitin-mediated sorting, making it relevant to cell biology, pharmacology, and metabolic disease research.
• Controls the number of LDL receptors on the cell surface and thus the rate of LDL cholesterol clearance.
• Dysregulation of LDL receptor catabolism contributes to familial hypercholesterolemia and atherosclerosis.
• IDOL-mediated ubiquitination of LDLR is a key regulatory mechanism responsive to cholesterol status.
• Provides a model for understanding ubiquitin-dependent receptor degradation and endosomal sorting.
• Relevant to neurodegenerative disease research, as LDL particle size subfractions have been linked to cerebral amyloidosis.
• Impacts drug development, since statins and other lipid-lowering agents influence LDL receptor levels.
• Important for understanding receptor-independent LDL cargo transfer and membrane interactions.
• Connects to endothelial scavenger receptor biology and vascular function.
• Influenced by hormonal signals such as estrogen, which can modulate LDL transcytosis.
• Enables CRISPR-based functional genomics studies of cholesterol metabolism.
What Happens During low-density lipoprotein particle receptor catabolic process?
Ligand binding and receptor internalization
In simple terms: The LDL receptor grabs LDL particles on the cell surface and pulls them inside.
The LDL receptor binds apolipoprotein B100 on LDL particles at the cell surface, forming a receptor-ligand complex that is internalized via clathrin-coated pits. This step is the starting point for both cholesterol delivery and receptor catabolism, because the receptor enters the endocytic pathway together with its ligand. Structural studies have revealed how apolipoprotein B100 engages the LDL receptor, providing a molecular basis for this interaction.
Endosomal sorting and receptor recycling
In simple terms: Inside the cell, the receptor can either be recycled back to the surface or sent for destruction.
After internalization, the acidic environment of the endosome causes the LDL particle to dissociate from the receptor. The receptor can then recycle back to the cell surface, while the LDL particle is delivered to the lysosome for degradation. The balance between recycling and degradation determines the size of the functional receptor pool, and this balance is regulated by cellular cholesterol levels.
Ubiquitination of the LDL receptor
In simple terms: A tag called ubiquitin is attached to the receptor, marking it for breakdown.
The E3 ubiquitin ligase IDOL (also known as MYLIP) is induced by liver X receptor (LXR) and ubiquitinates the LDL receptor, targeting it for degradation. This ubiquitination is a regulated step that responds to cholesterol status and provides a mechanism for feedback control of cholesterol uptake. IDOL-mediated degradation of LDLR is a well-characterized example of ligand-independent receptor downregulation.
Lysosomal degradation of the receptor
In simple terms: The tagged receptor is delivered to the lysosome and broken down into amino acids.
Ubiquitinated LDL receptors are sorted into the endosomal-lysosomal pathway and degraded in lysosomes. This degradation step completes the catabolic process and reduces the number of receptors available for further LDL binding. The breakdown products, including amino acids, are recycled by the cell.
Regulation by cholesterol and hormones
In simple terms: The cell adjusts how fast it destroys LDL receptors based on its cholesterol needs and signals.
When cellular cholesterol is abundant, the cell reduces LDL receptor levels by increasing catabolism, partly through LXR-driven IDOL expression. Hormonal signals such as estrogen can also influence LDL transcytosis and receptor biology in endothelial cells. This feedback regulation ensures that cholesterol uptake matches cellular demand and prevents excessive cholesterol accumulation.
Key Genes Involved in GO:0032802 low-density lipoprotein particle receptor catabolic process
The following genes and proteins are central to the low-density lipoprotein particle receptor catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Encodes the LDL receptor, the substrate of the catabolic process | Mutations cause familial hypercholesterolemia; target for cholesterol-lowering research |
| MYLIP (IDOL) | E3 ubiquitin ligase that ubiquitinates LDLR and targets it for degradation | Key regulator of LDLR catabolism; potential drug target |
| APOB | Apolipoprotein B100 ligand that binds LDLR | Structural studies of LDLR-ligand interaction |
| NR1H3 (LXR-alpha) | Nuclear receptor that induces IDOL expression in response to cholesterol | Links cholesterol sensing to LDLR degradation |
| NR1H2 (LXR-beta) | Nuclear receptor partner in regulating IDOL and cholesterol metabolism | Modulates LDLR catabolism |
| PCSK9 | Secreted protease that promotes LDLR degradation | Therapeutic target for cholesterol lowering |
| SCARB1 | Scavenger receptor involved in HDL and lipoprotein uptake | Related to endothelial scavenger receptor biology |
| CLTC | Clathrin heavy chain involved in endocytosis of LDLR | Required for receptor internalization |
| UBC | Ubiquitin conjugating enzyme in ubiquitination cascades | Participates in IDOL-mediated LDLR ubiquitination |
| UBB | Ubiquitin precursor protein | Provides ubiquitin for receptor tagging |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis, co-regulated with LDLR | Cholesterol homeostasis studies |
| SREBF2 | Transcription factor regulating cholesterol-related genes | Controls LDLR expression and feedback |
| ESR1 | Estrogen receptor influencing LDL transcytosis | Hormonal regulation of lipoprotein traffic |
| APOE | Apolipoprotein involved in lipoprotein metabolism | Linked to cerebral amyloidosis and lipid biology |
| LRP1 | Related LDL receptor family member in endocytosis | Comparative studies of receptor catabolism |
| VPS35 | Retromer component involved in endosomal sorting | Endosomal trafficking of receptors |
| TSG101 | ESCRT component in receptor sorting | Lysosomal targeting of ubiquitinated receptors |
How Is low-density lipoprotein particle receptor catabolic process Regulated?
The catabolic process of the LDL receptor is regulated at multiple levels. Cellular cholesterol status controls the expression of IDOL (MYLIP) through the liver X receptor (LXR), so that high cholesterol increases LDLR ubiquitination and degradation. The transcription factor SREBP-2 regulates LDLR gene expression in response to sterol levels, coupling synthesis and catabolism. Hormonal signals such as estrogen can modulate LDL transcytosis and receptor availability in endothelial cells. Additionally, the endosomal sorting machinery, including retromer and ESCRT components, determines whether internalized receptors recycle or are degraded.
low-density lipoprotein particle receptor catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia, atherosclerosis | LDLR knockout HepG2 cells; point-mutation knock-in |
| MYLIP (IDOL) | Cholesterol homeostasis, LDLR degradation | IDOL overexpression and knockout cell lines |
| APOB | LDL particle assembly and binding | APOB knock-in for structural studies |
| APOE | Cerebral amyloidosis, lipid metabolism | APOE isoform knock-in neurons |
| ESR1 | LDL transcytosis, vascular biology | ESR1 knockout endothelial cells |
Familial hypercholesterolemia and atherosclerosis
Loss-of-function mutations in LDLR cause familial hypercholesterolemia, characterized by high plasma LDL cholesterol and premature atherosclerosis. Altered catabolism of the LDL receptor can reduce the number of functional receptors on the cell surface, contributing to disease severity. Understanding LDLR degradation pathways may inform therapies that stabilize the receptor.
Neurodegeneration and cerebral amyloidosis
LDL particle size subfractions have been associated with cerebral amyloidosis, suggesting a link between lipoprotein metabolism and Alzheimer's disease-related pathology. Apolipoproteins such as APOE are involved in both lipid transport and amyloid deposition. Research into LDL receptor catabolism may clarify how lipid handling contributes to neurodegeneration.
Cardiovascular and endothelial biology
Endothelial scavenger receptors participate in lipoprotein uptake and vascular function. Estrogen has been shown to reduce LDL transcytosis, indicating hormonal control of lipoprotein movement across endothelium. These processes are relevant to atherosclerosis and vascular disease.
From low-density lipoprotein particle receptor catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDLR affect cholesterol uptake? | LDLR knockout cell line (e.g., HepG2) |
| How does IDOL regulate LDLR stability? | MYLIP overexpression and knockout cells |
| What is the effect of a specific LDLR mutation? | Point-mutation knock-in via CRISPR |
| How does tagged LDLR behave in live cells? | Tagged knock-in (e.g., GFP-LDLR) |
| Does overexpression of PCSK9 alter LDLR levels? | PCSK9 overexpression cell model |
| Which genes modify LDLR catabolism? | CRISPR library screening in cholesterol-reporting cells |
How to Study the low-density lipoprotein particle receptor catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | LDLR protein levels | Assessing degradation after IDOL induction |
| Pulse-chase | Receptor turnover rate | Measuring catabolic kinetics |
| Fluorescence microscopy | Receptor localization and trafficking | Visualizing endosomal sorting |
| Cryo-EM | Structure of LDLR-ligand complex | Understanding binding interface |
| CRISPR knockout screening | Genes affecting LDLR levels | Discovery of novel regulators |
| Cholesterol assay | Cellular cholesterol content | Functional readout of LDL uptake |
| Lipoprotein profiling | LDL particle size and subfractions | Linking to disease phenotypes |
Biochemical assays for receptor degradation
Western blotting and pulse-chase experiments measure LDLR protein levels and turnover rates, allowing researchers to quantify catabolism. These methods are typically applied to cells treated with cholesterol or LXR agonists to induce IDOL-mediated degradation.
Imaging and trafficking studies
Fluorescence microscopy and live-cell imaging of tagged LDLR reveal internalization, endosomal sorting, and lysosomal delivery. Structural studies such as cryo-EM provide atomic details of LDLR-ligand complexes.
CRISPR-based functional genomics
CRISPR knockout and library screening identify genes that regulate LDLR catabolism, including E3 ligases and sorting factors. These approaches enable unbiased discovery of novel regulators.
Lipid and lipoprotein measurements
Cholesterol quantification and lipoprotein profiling assess the functional consequences of altered LDLR catabolism. These assays are used in both cell culture and animal models.
How CRISPR Can Be Used to Study GO:0032802 low-density lipoprotein particle receptor catabolic process
Knockout
CRISPR knockout of LDLR or MYLIP (IDOL) in cell lines such as HepG2 or HeLa allows researchers to study the consequences of losing the receptor or its regulator. LDLR knockout cells show reduced LDL uptake, while IDOL knockout cells show stabilized LDLR.
Point Mutation
Point mutations in LDLR that mimic familial hypercholesterolemia variants can be introduced to study their impact on receptor folding, binding, and catabolism. This approach helps dissect which domains are required for degradation.
Knock-in
Knock-in of tagged LDLR (e.g., GFP or HA) enables live-cell imaging and biochemical tracking of the receptor through the endosomal-lysosomal pathway. Knock-in of disease-associated APOE alleles can model lipid-related neurodegeneration.
Overexpression
Overexpression of IDOL or PCSK9 promotes LDLR degradation and can be used to test whether a candidate gene modifies catabolism. Overexpression of LDLR itself can enhance cholesterol uptake and is useful for studying saturation of the pathway.
How EDITGENE Supports low-density lipoprotein particle receptor catabolic process Research
Researchers studying low-density lipoprotein particle receptor catabolic process-related genes often need to determine whether a candidate gene is causally involved in receptor degradation, cholesterol handling, or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible experiments to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for low-density lipoprotein particle receptor catabolic process research.
Frequently Asked Questions About low-density lipoprotein particle receptor catabolic process
What is GO:0032802?
GO:0032802 is the Gene Ontology term for the low-density lipoprotein particle receptor catabolic process, the breakdown of the LDL receptor protein.
What genes are involved in low-density lipoprotein particle receptor catabolic process?
Key genes include LDLR, MYLIP (IDOL), APOB, NR1H3 (LXR-alpha), and PCSK9.
How is the LDL receptor degraded?
The LDL receptor is ubiquitinated by IDOL and sorted to lysosomes for degradation.
What is the role of IDOL in LDL receptor catabolism?
IDOL is an E3 ubiquitin ligase that tags the LDL receptor with ubiquitin, marking it for degradation.
Why is LDL receptor catabolism important for cholesterol?
It controls the number of receptors available to clear LDL cholesterol from the blood.
What diseases are linked to LDL receptor catabolism?
Familial hypercholesterolemia, atherosclerosis, and possibly cerebral amyloidosis.
How can CRISPR be used to study LDL receptor catabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of the pathway.
What methods measure LDL receptor degradation?
Western blot, pulse-chase, fluorescence microscopy, and CRISPR screening are commonly used.
Does estrogen affect LDL receptor biology?
Estrogen has been shown to reduce LDL transcytosis in endothelial cells.
What are the synonyms for GO:0032802?
Synonyms include LDL receptor degradation, LDL receptor catabolism, and low-density lipoprotein receptor breakdown.
Conclusion
GO:0032802, low-density lipoprotein particle receptor catabolic process, is a fundamental biological process that controls cholesterol uptake by regulating the abundance of the LDL receptor. Its dysregulation is linked to familial hypercholesterolemia, atherosclerosis, and potentially neurodegenerative conditions. Advances in structural biology and CRISPR-based functional genomics continue to reveal new details about how the receptor is recognized, ubiquitinated, and degraded. Researchers can leverage EDITGENE's CRISPR cell model services to interrogate this pathway with precision and reproducibility.
References
- 1. Goldstein JL et al.. 2009. The LDL receptor.. Arterioscler Thromb Vasc Biol 29(4):431-8 PMID: 19299327
- 2. Brown MS et al.. 1986. A receptor-mediated pathway for cholesterol homeostasis.. Science 232(4746):34-47 PMID: 3513311
- 3. Reimund M et al.. 2025. Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor.. Nature 638(8051):829-835 PMID: 39663455
- 4. Zelcer N et al.. 2009. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.. Science 325(5936):100-4 PMID: 19520913
- 5. Axmann M et al.. 2019. Receptor-Independent Transfer of Low Density Lipoprotein Cargo to Biomembranes.. Nano Lett 19(4):2562-2567 PMID: 30848605
- 6. Adachi H et al.. 2006. Endothelial scavenger receptors.. Prog Lipid Res 45(5):379-404 PMID: 16712941
- 7. Lee S et al.. 2019. Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis.. J Alzheimers Dis 68(3):983-990 PMID: 30883362
- 8. Sessa WC. 2018. Estrogen Reduces LDL (Low-Density Lipoprotein) Transcytosis.. Arterioscler Thromb Vasc Biol 38(10):2276-2277 PMID: 30354224
